Details for New Drug Application (NDA): 061605
✉ Email this page to a colleague
NDA 061605 describes ETHRIL 500, which is a drug marketed by Bristol Myers Squibb and is included in one NDA. Additional details are available on the ETHRIL 500 profile page.
The generic ingredient in ETHRIL 500 is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.
The generic ingredient in ETHRIL 500 is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.
Summary for 061605
| Tradename: | ETHRIL 500 |
| Applicant: | Bristol Myers Squibb |
| Ingredient: | erythromycin stearate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 250MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 500MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
